Epstein-Barr virus in gastric adenocarcinomas: Association with ethnicity and CDKN2A promoter methylation

Journal of Clinical Pathology

Volumn 55, Issue 9, 2002, Pages 669-675

  Vo, Q N ^a   Geradts, J ^b   Gulley, M L ^d   Boudreau, D A ^a   Bravo, J C ^c   Schneider, B G ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSIDAD DEL VALLE   (Colombia)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; DNA METHYLATION; EPSTEIN BARR VIRUS; ETHNOLOGY; FEMALE; GENE INACTIVATION; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; MICROSATELLITE INSTABILITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; STOMACH ADENOCARCINOMA; STOMACH CANCER; SURVIVAL TIME;

ADENOCARCINOMA; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; DNA METHYLATION; DNA, NEOPLASM; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; GENE SILENCING; GENES, P16; HERPESVIRUS 4, HUMAN; HISPANIC AMERICANS; HUMANS; MALE; MICROSATELLITE REPEATS; MIDDLE AGED; PROMOTER REGIONS (GENETICS); STOMACH NEOPLASMS; UNITED STATES;

EID: 0036723954     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.55.9.669     Document Type: Article

References (84)

1. Helicobacter pylori infection and the risk of gastric carcinoma
2. Helicobacter infection in intestinal- and diffuse-type gastric adenocarcinomas
3. Human gastric carcinogenesis: A multistep and multifactorial process - First American Cancer Society award lecture on cancer epidemiology and prevention
4. Association of Epstein-Barr virus with undifferentiated gastric carcinomas with intense lymphoid infiltration. Lymphoepithelioma-like carcinoma
5. Epstein-Barr virus-associated gastric adenocarcinoma
6. Epstein-Barr virus and carcinomas. Expression of the viral genome in an undifferentiated gastric carcinoma
7. Epstein-Barr virus-associated gastric adenocarcinoma among Japanese Americans in Hawaii
8. Epstein-Barr virus in gastric carcinoma
9. Epstein-Barr virus and gastric cancer: Data and unanswered questions
10. Epstein-Barr virus and carcinomas: Rare association of the virus with gastric adenocarcinomas
11. Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein
12. Association of Epstein-Barr virus with gastric carcinoma with lymphoid stroma
13. Epstein-Barr virus and gastric remnant cancer
14. Helicobacter pylori and Epstein-Barr virus infection and the p53 tumour suppressor pathway in gastric stump cancer compared with carcinoma in the non-operated stomach
15. Microsatellite instability and Epstein-Barr virus infection in gastric remnant cancers
16. Epstein-Barr virus in gastric carcinomas with lymphoid stroma
17. Epstein-Barr virus-associated gastric carcinomas: Relation to H. pylori infection and genetic alterations
18. Epstein-Barr virus and gastric carcinoma
19. Clonal Epstein-Barr virus in lymphoepithelioma-like carcinoma of the stomach
20. Monoclanal Epstein-Barr virus genomes but lack of EBV-related protein expression in different types of gastric carcinoma
21. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus infection of the stomach
22. Epstein-Barr virus infection is an early event in gastric carcinogenesis and is independent of bcl-2 expression and p53 accumulation
23. Epstein-Barr virus promotes epithelial cell growth in the absence of EBNA2 and LMP1 expression
24. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4
25. INK4a
26. A cell-cycle regulator potentially involved in genesis of many tumor types
27. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
28. p16 gene in uncultured tumors
29. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers
30. Frequency of homozygous deletion of p16/CDKN2 in primary human tumours
31. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer
32. Role of the p16 tumor suppressor gene in cancer
33. INK4a/CDKN2A tumor suppressor and its relatives
34. Overexpression of mutant p53 and c-erbB-2 proteins and mutations of the p15 and p16 genes in human gastric carcinoma: With respect to histological subtypes and stages
35. Frequent detection of aberrant RNA transcripts of the CDKN2 gene in human gastric adenocarcinoma
36. Mutation frequency of the p16/CDKN2 gene in primary cancers of the upper digestive tract
37. Loss of heterozygosity on the short arm of chromosome 9 without p16 gene mutation in gastric carcinomas
38. INK4B genes in gastric carcinomas
39. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas
40. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach
41. The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma
42. Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population
43. A National Cancer Institute workshop on microsatellite instability for cancer detection and familial predisposition: Development of international criteria for the determination of microsatellite instability in colorectal cancer
44. Comparison of bisulfite modification of 5-methyldeoxycytidine and deoxycytidine residues
45. Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands
46. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p161NK4A in archival human solid tumors: Correlation with retinoblastoma protein
47. Loss of Fhit expression in non-small-cell lung cancer: Correlation with molecular genetic abnormalities and clinicopathological features
48. Epstein-Barr virus-associated gastric carcinoma in Mexico: Analysis of 135 consecutive gastrectomies in two hospitals
49. A children's cancer dependent on climatic factors
50. Burkitt lymphoma in New Guinea: Establishment of a line of lymphoblasts in vitro and description of their fine structure
51. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: Association with mixed cellularity subtype and Hispanic American ethnicity
52. The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma
53. INK4a expression
54. Epstein-Barr virus infection is associated with p53 accumulation in nasopharyngeal carcinoma
55. Absence of nuclear p16 from Epstein-Barr virus-associated undifferentiated nasopharyngeal carcinomas
56. Immunophenotypic characterization of Epstein-Barr virus-associated gastric carcinoma: Massive infiltration by proliferating CD8+ T-lymphocytes
57. Human cytotoxic T lymphocyte responses to Epstein-Borr virus infection
58. Increased frequency of antigen-specific CD+ cytotoxic T lymphocytes infiltrating an Epstein-Barr virus-associated gastric carcinoma
59. Why is CpG suppressed in the genomes of virtually all small eukaryotic viruses but not those of large eukaryotic viruses?
60. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear-antigen-2 and latent-membrane-protein genes in cells latently infected with Epstein-Barr virus
61. CpG methylation of viral DNA in EBV-associated tumors
62. Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: Evidence that demethylation at a single CpG site is crucial
63. CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease
64. Methylation of the Epstein-Barr virus genome in normal lymphocytes
65. Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease - Application of PCR-based analysis
66. Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP1 and BCR2 enhancer-promoter regions
67. Variable expression of latent membrane protein in nasopharyngeal carcinomas can be related to methylation status of the Epstein-Barr virus BNLF-1 5′ flanking region
68. The role of DNA methylation in modulating Epstein-Barr virus gene expression
69. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells
70. The truncated form of the Epstein Barr virus latent-infection membrane protein does not transform rodent fibroblasts
71. All three domains of the Epstein-Barr virus-coded latent membrane protein LMP-1 are required for transformation of rodent fibroblasts
72. Epstein-Barr virus infection in non-carcinomatous gastric epithelium
73. Transcriptional analysis of Epstein-Barr virus gene expression in EBV-positive gastric carcinoma: Unique viral latency in the tumour cells
74. Unique transcription pattern of Epstein-Barr Virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene
75. A transforming function of the BARF1 gene encoded by Epstein-Barr virus
76. Establishment of a monkey kidney epithelial cell line with the BARF1 open reading frame from Epstein-Barr virus
77. Expression and tumorigenicity of the Epstein-Barr virus BARF1 gene in human Louckes B-lymphocyte cell line
78. The Epstein-Barr virus BARF1 gene encodes a novel, soluble colony-stimulating factor-1 receptor
79. CSF-1 signal transduction
80. Origin of microsatellite instability in gastric cancer
81. Correlation of methylation of the hMLH1 promoter with lack of expression of hMLH1 in sporadic gastric carcinomas with replication error
82. Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor